Literature DB >> 18552274

Icodextrin and intraperitoneal inflammation.

Misaki Moriishi1, Hideki Kawanishi.   

Abstract

BACKGROUND: The peritoneum is impaired by exposure to biocompatible dialysis solutions. Because icodextrin peritoneal dialysis fluid (PDF) is made from cornstarch, a possibility that it induces intraperitoneal inflammation has been reported. In the present study, patients on glucose PDF were switched to icodextrin PDF and then switched back to glucose PDF. Icodextrin PDF-induced intraperitoneal inflammation was investigated based on changes in peritoneal permeability and inflammatory reactions. PATIENTS AND METHODS: The subjects were 7 stable peritoneal dialysis patients (4 men, 3 women), with a mean age of 59.1 +/- 3.8 years (range: 55.2 - 64.6 years). The mean duration of peritoneal dialysis was 58.3 +/- 27.4 months (range: 34.3 - 97.7 months), and the cause of end-stage renal disease was chronic glomerulonephritis in all patients. For the overnight dwell, glucose PDF was changed to icodextrin PDF, and the patients returned to glucose PDF 30 months later. To evaluate peritoneal permeability, a peritoneal equilibrium test (PET) was performed, and dialysate-to-plasma (D/P) ratios of creatinine (Cr), beta(2)-microglobulin (beta2M), albumin, immunoglobulin G (IgG), and alpha(2)-macroglobulin (alpha2M) were measured in the overnight dialysate and serum. As markers of inflammation and fibrinolysis or coagulation, interleukin-6 (IL-6) and fibrinogen degradation products (FDPs) were measured in overnight effluent. The evaluations were made every 6 months for 36 months.
RESULTS: A significant elevation in FDP levels was detected in overnight effluent 6 months after the switch to icodextrin PDF, and IL-6 levels tended to increase. The D/P ratios of Cr, beta2M, and albumin were also significantly increased, and the D/P ratios of IgG and alpha2M tended to increase. The D/P ratio of Cr as measured by PET was slightly increased, but the elevation was not significant. In 5 patients, after icodextrin PDF was switched back to glucose PDF at 30 months, the D/P ratios of Cr, beta2M, albumin, IgG, and alpha2M in overnight effluent were significantly reduced. The FDP levels decreased slightly in those patients. In the remaining 2 patients, the D/P ratios of Cr on PET and of Cr, beta2M, albumin, IgG, and alpha2M in overnight effluent, and the FDP and IL-6 levels in overnight effluent were markedly elevated after the switching from glucose to icodextrin PDF, and they remained high after the switch back to glucose PDF. One of these 2 patients developed pre-EPS and was treated with prednisolone and concomitant hemodialysis. The other was switched from peritoneal dialysis to hemodialysis.
CONCLUSIONS: Icodextrin dialysis solution may induce an inflammatory reaction in the peritoneum. Further investigation is necessary for the long-term use of icodextrin PDF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552274

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  10 in total

1.  Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Authors:  Sylvie Opatrna; Daniel Lysak; Ladislav Trefil; Clare Parker; Nicholas Topley
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

2.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

3.  Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature.

Authors:  Periklis Dousdampanis; Konstantza Trigka; Maggie Chu; Saimah Khan; Daniele Venturoli; Dimitrios G Oreopoulos; Joanne M Bargman
Journal:  Int Urol Nephrol       Date:  2010-02-21       Impact factor: 2.370

4.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.

Authors:  Michaela C Brown; Keith Simpson; Jan J Kerssens; Robert A Mactier
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

5.  Risk factors of severe peritoneal sclerosis in chronic peritoneal dialysis patients.

Authors:  Sudabeh Alatab; Iraj Najafi; Gholamreza Pourmand; Mostafa Hosseini; Soroosh Shekarchian
Journal:  Ren Fail       Date:  2016-10-24       Impact factor: 2.606

Review 6.  Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.

Authors:  Stefanos Roumeliotis; Evangelia Dounousi; Marios Salmas; Theodoros Eleftheriadis; Vassilios Liakopoulos
Journal:  Biomolecules       Date:  2020-05-14

7.  Activation of General Control Nonderepressible-2 Kinase Ameliorates Glucotoxicity in Human Peritoneal Mesothelial Cells, Preserves Their Integrity, and Prevents Mesothelial to Mesenchymal Transition.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Evdokia Nikolaou; Spyridon Golfinopoulos; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Biomolecules       Date:  2019-12-05

8.  Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients.

Authors:  Periklis Dousdampanis; Konstantina Trigka; Joanne M Bargman
Journal:  Int J Nephrol       Date:  2013-01-08

Review 9.  Biocompatible Peritoneal Dialysis: The Target Is Still Way Off.

Authors:  Maria Bartosova; Claus Peter Schmitt
Journal:  Front Physiol       Date:  2019-01-07       Impact factor: 4.566

Review 10.  Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

Authors:  Rajesh M Jagirdar; Andreas Bozikas; Sotirios G Zarogiannis; Maria Bartosova; Claus Peter Schmitt; Vassilios Liakopoulos
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.